Activated T cells engage aerobic glycolysis and anabolic metabolism for growth, proliferation, and effector functions. We propose that a glucose-poor tumor microenvironment limits aerobic glycolysis in tumor-infiltrating T cells, which suppresses tumoricidal effector functions. We discovered a new role for the glycolytic metabolite phosphoenolpyruvate (PEP) in sustaining T cell receptor-mediated Ca 2+ -NFAT signaling and effector functions by repressing sarco/ER Ca 2+ -ATPase (SERCA) activity. Tumor-specific CD4 and CD8 T cells could be metabolically reprogrammed by increasing PEP production through overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which bolstered effector functions. Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice. This study uncovers new metabolic checkpoints for T cell activity and demonstrates that metabolic reprogramming of tumor-reactive T cells can enhance anti-tumor T cell responses, illuminating new forms of immunotherapy.
In Brief
High rates of tumor cell glycolysis suppress intratumoral T cell function by depriving T cells of glucose and the downstream metabolite phosphoenolpyruvate (PEP), which is necessary for maximal Ca 2+ -NFAT signaling in T cells. Metabolic rewiring of T cells to generate PEP in glucose-poor conditions improves their anti-tumor responses.
INTRODUCTION
Host immunity provides wide spectrum protection that serves to eradicate cancerous cells in addition to infectious pathogens. Multiple types of immune cells are involved in tumor immunosurveillance and of particular importance are the tumor-infiltrating lymphocytes (TILs) (i.e., T cells) (Braumü ller et al., 2013; Shiao et al., 2011) . In most established tumors, however, the tumoricidal effector functions of TILs such as IFNg production and cytotoxicity are restricted by multiple environmental factors. This includes the accumulation of immunoregulatory cells such as regulatory CD4+ T cells (Tregs), myeloid derived suppressor cells (MDSCs) and tolerogenic antigen-presenting cells (APCs) (Mellman et al., 2011; Shiao et al., 2011) . Additionally, alterations in the availability of nutrients (e.g., lactate and tryptophan-related metabolites such as kynurenine) in the tumor microenvironment can limit TIL activity . Another prominent feature of TILs is the increased expression of inhibitory checkpoint receptors (e.g., programmed cell death protein 1 [PD-1], lymphocyte-activation gene 3 [Lag3] , and cytotoxic T-lymphocyte-associated protein 4 ) that desensitizes T cell receptor (TCR) signaling and contributes to their functional impairment (Baitsch et al., 2012) . T cells displaying such properties are commonly referred to as ''functionally exhausted'' (Wherry, 2011) . These discoveries have led to the development of cancer immunotherapies that reawaken exhausted TILs by blocking inhibitory checkpoint receptors such as PD-1 or CTLA-4 or targeting other immunoregulatory cells. Adoptive cell therapy (ACT) of tumor-specific T cells is another promising form of anti-cancer immunotherapy that increases the repertoire of cytotoxic T cells to eradicate established tumors. ACT has the added benefit of permitting genetic modifications of TILs to express proteins that could aide in tumor destruction (Maude et al., 2014 ). These breakthroughs demonstrate that tumor immunotherapy holds great promise (Callahan et al., 2010; Wolchok et al., 2013) , but also present us with challenges to devise additional treatment options in conjunction with those currently available to further increase patient objective responses. To meet these challenges, we must gain a clearer understanding of what causes T cell exhaustion in tumors, and we hypothesize that the metabolic states of the TILs and tumor cells, as well as other cell types in the tumor microenvironment, are principal components of this process.
Deregulated anabolic metabolism and increased rates of aerobic glycolysis (i.e., the Warburg effect), glutaminolysis and fatty acid synthesis are cardinal features of most tumor cells that fuels their growth and proliferation (Hanahan and Weinberg, 2011; Ward and Thompson, 2012) . Interestingly, activated T lymphocytes undergo a metabolic switch similar to cancer cells and upregulate aerobic glycolysis and glutaminolysis to permit proliferation and differentiation into specialized effector T cells. Given their similarities in metabolic profiles and nutrient requirements, it is possible that the abnormally high metabolic rates and consumption of nutrients by tumor cells competes with neighboring T cells, which leads to T cell metabolic exhaustion that underlies their functional exhaustion. Supporting this notion, reports have shown that the concentration of extracellular glucose are lower in tumors compared to healthy tissues (Gullino et al., 1964) . Thus, limited glucose availability could be an environmental restriction that promotes T cell exhaustion, and if true, it is important to learn how this affects T cell receptor (TCR) signaling and effector functions in tumors. Perhaps, new therapies directed at reprogramming T cell metabolism could be developed to enhance their functional fitness in the tumor microenvironment.
TCR stimulation activates numerous key signaling pathways that coordinately induce anabolic metabolism, aerobic glycolysis, and effector T cell proliferation and differentiation (SmithGarvin et al., 2009) . Increased aerobic glycolysis is essential for the production of biosynthetic precursors that fuel effector T cell proliferation and production of effector molecules like IFNg, IL-2, and IL-17 and Granzyme B in T cells (Cham et al., 2008; Chang et al., 2013; Finlay et al., 2012; Michalek et al., 2011) . Activation of PI3K, Akt, and mTOR triggers the switch to anabolic metabolism by inducing transcription factors such as Myc and hypoxia-inducible factor 1 (HIF1) (MacIver et al., 2013; Wang et al., 2011a) . T cells rendered functionally anergic that are unable to activate Ca 2+ and nuclear factor of activated T cells (NFAT) signaling show diminished rates of aerobic glycolysis and anabolic metabolism following stimulation (Srinivasan and Frauwirth, 2007; Zheng et al., 2009) . Similarly, CD8 T cells with increased PD-1 expression fail to fully activate mTOR or aerobic glycolysis following TCR stimulation and conversely, those with hyper-HIF1a activity and aerobic glycolysis are refractory to functional exhaustion (Doedens et al., 2013; Parry et al., 2005; Staron et al., 2014) . The glycolytic enzymes may also serve direct roles in regulating effector functions in T cells because recent work showed that when glycolytic rates are low, the glyceraldehyde phosphate dehydrogenase (GAPDH) binds to and suppresses Ifng mRNA translation in T cells Gubser et al., 2013 ). These findings demonstrate strong interconnections between T cell metabolism and effector functions but little remains known about how metabolic pathways or their metabolites fine-tune T cell activity.
In this study, we found that intratumoral CD4 T cells displayed signs of glucose deprivation and diminished anti-tumor effector functions, suggesting that a glucose-poor tumor microenvironment might contribute to TIL exhaustion. Furthermore, increased expression of hexokinase 2 (HK2) in tumor cells allowed for more efficient evasion of CD4 T cell-mediated immune surveillance indicating that a metabolic competition could exist between TILs and tumor cells. Linking glucose-deprivation to T cell function, we also discovered that insufficiency of the glycolytic metabolite phosphoenolpyruvate (PEP) led to defects in Ca 2+ -NFAT signaling and T cell activation by increasing SERCA-mediated Ca 2+ re-uptake. Most importantly, we provided proof-of-concept evidence that metabolic reprogramming of T cells to increase PEP production could be a promising strategy to elevate T cell mediated anti-tumor immune responses and improve the effects of adoptive T cell transfer immunotherapy.
RESULTS
Glucose Limitation Suppresses Anti-tumor Effector Functions of Intratumoral TH1 CD4 T Cells while Stimulating TGFb Production To investigate whether limited glucose availability within the tumor microenvironment suppressed aerobic glycolysis and hence, effector functions in TILs, we first compared the concentration of glucose in the interstitial fluid of the spleen, blood, and tumors from melanoma-bearing Tyr-creERT2/BrafV600E/Ptenlox (Braf/Pten) mice (Dankort et al., 2009 ) ( Figure 1A ) and B16 melanoma-bearing mice (data not shown). As reported in other solid tumors (Gullino et al., 1964) , the glucose level of the tumor interstitial fluid ($0.6 mM) was approximately ten times lower than that of the spleen and blood ($9 mM). Additionally, intratumoral CD44hi CD25lo CD4+ T cells (i.e., activated non-Treg CD4+ T cells) failed to take-up glucose as efficiently as their counterparts in the spleen based on intracellular staining with the fluorescent glucose analog 2-NBDG ( Figure 1B) . We further assessed 2NDBG-uptake in tumor infiltrating non-Treg CD4+ T cells, Tregs, tumor-associated macrophages (TAMs), and MDSCs. This showed that non-Treg CD4+ T cells take-up marginally less 2NDBG than TAMs, but not MDCSs. Unexpectedly, the intramoral and splenic Tregs demonstrated higher 2NDBG uptake compared to the other cell populations ( Figure S1A ). Furthermore, co-culturing TH1 CD4+ T cells with Braf/Pten melanoma cells demonstrated that the presence of tumor cells could reduce glucose uptake by TH1 cells (Figure 1C) , suggesting that tumor cells may directly restrict glucose availability for TILs. As there is no facile way to directly and specifically measure rates of glycolysis in TILs in vivo or in situ, we attempted to determine if intratumoral CD4+ T cells express genes induced by glucose deprivation. We identified a ''glucosedeprivation transcriptional signature'' in CD4+ T cells by comparing the differentially expressed genes of activated TH1 cells cultured in high (10 mM) or low (0.1 mM) glucose concentrations using RNA-sequencing and microarrays ( Figure S1B ), and observed that intratumoral CD4+ T cells expressed higher levels of the glucose-deprived signature genes than CD4+ T cells in the draining lymph nodes (dLNs) ( Figure 1D ). This result suggested that some portion of the CD4+ TILs experienced glucose-deprivation within the tumor microenvironment in vivo.
Next, we stimulated functional TH1 CD4+ T cells (isolated from lymphocytic choriomeningitis virus (LCMV)-infected animals) in different concentrations of glucose (ranging from 0.1-10 mM) to directly interrogate the effects of glucose deprivation on production of CD40 ligand (CD40L) and IFNg-two factors critical for maintaining an immunostimulatory microenvironment in the Braf/Pten melanomas (Ho et al., 2014) . This showed that these effector functions were suppressed by limited amounts of glucose ( Figure 1E ). Conversely, glucose deprivation augmented TGFb production in activated CD4+ T cells ( Figure 1F ), suggesting that glucose deprivation can cause CD4+ T cells to switch from immuno-supportive to immuno-suppressive states. Importantly, the CD4+ T cells isolated directly ex vivo from melanomas displayed similar functional attributes to the in vitro glucosedeprived TH1 cells. For example, the percentage of CD44hi CD25lo (non-Treg) CD4+ T cells that produced IFNg or CD40L in the tumors was $50% lower than that in the spleen or dLN ( Figure 1G) . Additionally, the expression of the TGFb latency associated peptide (LAP), a surrogate marker for cells competent to produce TGFb, was examined on the CD4+ T cells , and this showed that a greater proportion of nonTreg CD4+ T cells expressed elevated LAP compared to the FoxP3+ Tregs in both the tumors and dLNs ( Figure 1J ). Data shown are cumulative of two (A and B, D, H, I) (n = 3-6 mice/group/experiment) and three (G and J) independent experiments (n = 3-4 mice/group/ experiment) or representative of three (C, E and F) independent experiments (n = 3-5/group). Data are expressed as mean ± SD and (C) is presented as mean ± SEM. *p < 0.05 by unpaired Student's t test.
Collectively, these data demonstrate that CD4+ TILs display genetic and functional features associated with glucose-deprivation and suggest that competition between tumor cells and TILs for glucose in the tumor microenvironment could contribute to an immunosuppressive environment.
Increased Rates of Aerobic Glycolysis in Melanoma
Cells Suppress CD4+ T Cell-Mediated Immunosurveillance Increased rates of aerobic glycolysis and expression of glycolytic enzymes (e.g., hexokinase 2 [Hk2]) are common hallmarks of cancer cells (Hanahan and Weinberg, 2011) , and this may lead to glucose-deprivation and T cell dysfunction in tumors as suggested by the data above. To investigate this hypothesis further, we analyzed the expression of effector T cell genes (e.g., Ifng and Cd40lg) and markers of glycolysis (e.g., Hk2) mRNA within the tumors of 384 melanoma patients (data obtained from The Cancer Genome Atlas [TCGA]) (Cerami et al., 2012; Gao et al., 2013) . Interestingly, this showed that the amount of Cd40lg and Ifng mRNA inversely correlated with Hk2 mRNA ( Figure S2A ). To more directly test if the glycolytic rates of tumor cells affect tumor immunosurveillance by CD4+ T cells, we established stable clones of the Braf/Pten melanoma cell line (YUMM1.7) that expressed either a control vector or one overexpressing HK2 (HK2-OE). As expected, HK2-OE tumor cells had higher rates of aerobic glycolysis than the control cells based on extracellular acidification rates (ECAR) using the Seahorse Extracellular Flux Analyzer ( Figure S2B ) and HK2-OE tumor cells more efficiently suppressed glucose uptake of TH1 CD4+ T cells in the co-culture assay ( Figure S2C ). Then we engrafted control and HK2-OE melanoma cell lines into the left and right flanks, respectively, of wild-type C57BL/6 mice. Two weeks later, the production of CD40L and IFNg by CD4+ TILs restimulated directly ex vivo was assessed and compared to CD4+
T cells isolated from the control melanomas, those isolated from HK2-OE tumors had lower production of CD40L and IFNg (Figures 2A and 2B and S2D) . This result demonstrated that T cell effector functions could be affected by the rates of tumor cell aerobic glycolysis. Next, we compared the growth rates of control and HK2-OE melanoma cell lines engrafted into the left and right flanks, respectively, of Rag1-KO mice that were either reconstituted with CD4+ T cells or not. In accord with higher rates of aerobic glycolysis, the HK2-OE melanomas grew faster compared to the control tumors in both groups of mice (Figure 2C) . However, the presence of CD4+ T cells potently suppressed the growth of control melanoma cells, but had little effect on the HK2-OE melanoma cells ( Figures 2C-2E ). Taken together, these results support the intriguing model that tumor cells with increased rates of aerobic glycolysis are better able to evade anti-tumor CD4+ T cell responses.
Glucose Deprivation Suppresses TCR-Dependent Activation of Ca 2+ and NFAT Signaling To better understand how glucose deprivation alters TH1 cell functions, we examined how glycolysis affects TCR signaling after TCR stimulation using several approaches. First, we observed that the induction of the immediate early gene Nur77 (as measured using a Nur77-eGFP reporter that reads out TCR signaling in a Ca 2+ -dependent manner; Moran et al., 2011) was suppressed in glucose-poor conditions or in the presence of 2-DG ( Figure 3A ). In contrast, the amount of phosphorylated ERK1/2 (pERK1/2) or AKT (pAKTS473 and pAKTT308) was minimally affected following activation of TH1 CD4 T cells in glucose-deprived conditions ( Figure S3 ). The defect in Nur77 induction prompted us to more closely monitor cytoplasmic calcium flux using the ratiometric Ca flux in activated TH1 cells ( Figure 3B ). Moreover, reducing aerobic glycolysis in activated TH1 cells by glucose deprivation or deletion of the glucose transporter 1 (Macintyre et al., 2014) also suppressed ionomycin-induced cytoplasmic Ca 2+ accumulation ( Figures 3C and 3D ). This latter result indicated that the defect in Ca 2+ flux could be IP3-independent because ionomycin triggers Ca 2+ efflux from the ER in an IP3-independent manner.
In agreement, glucose deprivation did not affect TCR-induced phosphorylation of PLCg-1 in TH1 cells ( Figure 3E ). Altogether, these results suggested that glucose-deprivation dampened the magnitude of TCR-induced Ca 2+ flux, and consequently CD4+ T cell effector functions. Interestingly, anergic T cells, which have similar functional defects to those observed with glucose-deprivation, also (F) T H 1 cells were stimulated with ionomycin in medium containing 10 mM or 0.1 mM glucose for 10 min and the cytoplasmic versus nuclear distribution of NFAT1 and NFAT2 was determined by Amnis Imagestream. Representative histograms and images show the similarity profiles of NFAT1 (yellow, left) or NFAT2 (red, right) with DAPI staining to measure nuclear localization. The percentage of T cells with nuclear NFAT1 or NFAT2 is shown.
(G) Heat map shows normalized expression of select genes associated with T cell anergy (Safford et al., 2005) in T H 1 cells stimulated for 5 hr with anti-CD3/anti-CD28 mAbs in glucose-sufficient (10 mM) or glucose-deficient (0.1 mM) conditions. Data shown are representative of two (D and E) and three (A-C, F) independent experiments or cumulative of three (G) independent experiments (n = 2 mice/ group).
display defects in Ca 2+ signaling (Schwartz, 2003) . Other work has shown that the reduced Ca 2+ signaling in anergic CD8 T cells impairs the nuclear localization of NFAT1, but not that of NFAT2, indicating differential sensitivity to cytoplasmic Ca 2+ levels between these two transcription factors (Srinivasan and Frauwirth, 2007) . These phenotypes prompted us to examine the cellular distribution of NFAT1 and 2 and expression of anergy-associated genes in glucose-deprived TH1 cells (Safford et al., 2005) . In agreement with the prior study (Srinivasan and Frauwirth, 2007) , nuclear translocation of NFAT1, but not NFAT2, was severely compromised in glucosedeprived TH1 cells ( Figure 3F ). Importantly, 5 hr of glucose deprivation led to increased expression of several ''anergy'' signature genes, including Egr2, Egr3, Irf4, Hspa1a, Gadd45b, and Nfatc1 as previously described ( Figure 3G , note the augmented expression of some of these genes in TILs in Figure 1D) (Safford et al., 2005) . Collectively, these results identified that glycolysis is critical for sustaining high amounts of Ca 2+ -NFAT signaling in TH1 cells and that glucose-deprivation results in CD4 T cell dysfunction and expression of anergyassociated genes.
Glycolysis Modulates SERCA-Mediated ER Calcium Uptake Activity Stimulation of the TCR initially triggers Ca 2+ efflux from the ER, which subsequently induces extracellular Ca 2+ import via the calcium-release-activated calcium (CRAC) channel (Feske et al., 2012 Figure S4 ). This result suggested that glucose-deprived T cells have increased SERCA activity that suppressed maximal Ca 2+ flux. Importantly, Tg treatment also restored nuclear translocation of NFAT1 ( Figure 4C ) as well as IFNg and CD40L production ( Figure 4D ) in 2-DG treated TH1 cells. Western blotting of Jurkat T cells showed that 2-DG treatment did not affect the overall amounts of SERCA compared to control cells ( Figure 4E ), suggesting that the increase in ER Ca 2+ re-uptake stemmed from increased SERCA activity. Indeed, measurement of radio-labeled Ca 2+ uptake in ER vesicles isolated from Jurkat T cells revealed that 2-DG treatment increased SERCA-dependent Ca 2+ uptake by $2-fold compared to the control cells ( Figure 4F ). Taken together, these findings strongly indicate that glycolysis suppresses SERCA activity and consequently, glucose deprivation leads to defective Ca 2+ -NFAT signaling and effector functions in glucose-deprived T cells. The Glycoloytic Metabolite Phosphoenolpyruvate Regulates Ca 2+ -NFAT Signaling in TH1 CD4+ T Cells by Inhibiting SERCA Activity To determine which steps of glycolysis regulate cytoplasmic Ca 2+ accumulation and T cell effector functions, TH1 cells were treated with 2-DG, iodoacetate (IAA) and oxalate (OXA), to inhibit hexokinase (HK), glyceraldehyde phosphate dehydrogenase (GAPDH), and pyruvate kinase (PK), respectively, at doses that showed comparable inhibition of lactate production ( Figure 5A and data not shown). The glycolytic metabolites were examined by high-resolution liquid-chromatography Q-exactive mass spectrometry (LC-QE-MS) in the CD4+ T cells stimulated in the absence or presence of the inhibitors and as expected, the levels of 3-and 2-phosphoglycerate (3-PG/2-PG), and phosphoenolpyruvate (PEP) were suppressed by 2-DG and IAA, but promoted by OXA ( Figures 5B and S5A) . Interestingly, 2-DG and IAA, but not OXA, suppressed TH1 cell Ca 2+ flux after ionomycin stimulation ( Figure 5C ) and CD40L and IFNg production after TCR stimulation ( Figures 5D and 5E ). Likewise 2-DG and IAA, but not OXA, augmented TGFb production -uptake assay as described in Figure 4F was performed on ER microsomal fractions isolated from Jurkat T cells cultured in the presence or absence of glucose or exogenous PEP. The addition of Tg served as a specificity control for SERCA-dependent activity. Data shown are representative of two (H and J) and three (C and D, G and I) independent experiments or cumulative of three (B, E and F) independent experiments. Data are expressed as mean ± SD and *p < 0.05 by unpaired Student's t test.
( Figure 5F ). These results suggested that a metabolite produced downstream of GAPDH and upstream of PK fine-tunes Ca 2+ signaling and TH1 effector functions.
We hypothesized that such a metabolite may be PEP because of the above inhibitor studies and because TCR activation increases expression of the less-active M2 isoform of pyruvate kinase (PKM2) (Wang et al., 2011a) , which allows the accumulation of several metabolic intermediates, including PEP, in proliferating cells (Vander Heiden et al., 2010) . To more rigorously confirm the role of PEP in regulating the Ca 2+ -NFAT pathway, we knocked down enolase 1 (Eno-1), the glycolytic enzyme that converts 2-PG into PEP ( Figure S5B ), and analyzed NFAT1 nuclear translocation and expression of IFNg and CD40L in activated CD4+ T cells. This showed that NFAT1 nuclear translocation and the production of IFNg and CD40L ( Figures 5G and 5H) were impaired by Eno-1 knock down. Additionally, treating TH1 CD4+ T cells with PKM2 activator DASS, which will decrease intracellular PEP levels (data not shown) (Anastasiou et al., 2012) , similarly suppressed the production of IFNg and CD40L ( Figure S5C ). Finally, supplementation of PEP (1 mg/ml), but not fosfomycin (a structurally related analog), to glucose-deprived CD4+ T cells restored Ca 2+ flux in the presence of IAA (Figures 5I and S5D ). Together these experiments narrowing in on the enzymes regulating PEP metabolism in cells, demonstrate that the accumulation of PEP is critical for sustaining Ca 2+ -NFAT signaling. To directly test if PEP can inhibit SERCA-mediated calcium uptake, we repeated the ER Ca 2+ uptake assay by isolating ER vesicles from Jurkat T cells cultured in the presence or absence of glucose. This showed that glucose deprivation promoted ER Ca 2+ uptake ability; however, PEP supplementation to the ER vesicle fraction significantly suppressed ER Ca 2+ uptake indicating that PEP can inhibit SERCA activity ( Figure 5J ). Given that oxidation of SERCA on cysteine residues (e.g., Cys674 and Cys675) reduces SERCA activity (Sharov et al., 2006) , we then examined whether glucose deprivation in T cells affects the redox state of SERCA using fluorescent thiol probes that measure the abundance of reduced cysteine residues on proteins. Jurkat T cells were cultured in glucose-replete or -deplete conditions, and ER vesicles were isolated and labeled with fluorescent probes that covalently bind to free thiols. SERCA was then immunoprecipitated from the ER vesicles and the amount of sample fluorescence measured indicated the abundance of reduced cysteines in SERCA. ER vesicles from glucose-deprived cells treated with H 2 O 2 or b-mercaptoethanol (b-ME) served as positive controls for maximal cysteine oxidation and reduction, respectively. These experiments showed that compared to cells cultured in glucose-replete medium, glucose-deprivation increased the abundance of free thiols on SERCA, indicative of a more reduced state ( Figure S5E ). The addition of PEP, but not fosphomycin, to the ER vesicles decreased thiol abundance on SERCA similar to the amounts observed with H 2 O 2 ( Figure S5E ). This result suggests that PEP likely impairs SERCA activity by promoting cysteine oxidation. To further explore this possibility, we found that treating glucose-deprived CD4+ T cells with H 2 O 2 , which suppresses SERCA activity via cysteine oxidation (Qin et al., 2013) , could restore their ability to flux Ca 2+ ( Figure S5F ). Collectively, these results identify a previously uncharacterized role for the metabolite PEP in controlling Ca 2+ signaling through inhibition, and likely the oxidation, of SERCA in T cells. These findings elucidate a nutrient-sensing mechanism by which T cells integrate their functional states with their metabolic states.
Metabolic Reprogramming of TILs Boosts Tumoricidal
Activities in the Glucose-Deprived Tumor Microenvironment The above findings support a model whereby the hyper-anabolic metabolic states of tumor cells reduce the availability of nutrients, such as glucose, and prevent TILs from sustaining Ca 2+ -NFAT signaling and effector functions, in part, from PEP insufficiency. If so, it may be possible to metabolically reprogram anti-tumor T cells to increase their fitness and function in the tumor microenvironment. Because the data indicated that PEP was a critical metabolite controlling T cells function, we speculated that overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which converts oxaloacetate (OAA) into PEP, could bolster the tumoricidal activity of TILs ( Figure 6A ). To examine this hypothesis, PCK1 (PCK1-OE) was overexpressed in Trp-1 CD4+ T cells specific for the melanoma antigen gp75/tyrosinase-related protein 1 (TRP-1), and this demonstrated that PCK1-OE specifically boosted PEP levels in T cells cultured in glucose-poor conditions ( Figure 6B , compare blue and green bars), but had little effect on the amount of PEP above and beyond that normally found in T cells cultured in glucose-rich conditions. In contrast to control cells, PCK1-overexpression also reversed the effects of glucose-deprivation on Ca 2+ flux and NFAT1 nuclear localization in CD4+ T cells ( Figures 6C and 6D ). It is important to note that the effects of glucose deprivation and PCK1-OE on CD8 T cell Ca 2+ flux and effector functions were very similar to those observed in CD4 T cells. For example, blocking PEP accumulation via glycolytic inhibitors or PKM2 activators also diminished CD8+ T cell IFNg production ( Figures S6A and S6B) . Additionally, PCK1-overexpression restored Ca 2+ flux in glucose-deprived CD8+ T cells ( Figure S6C ). Thus, PCK1-OE lessened the dependence of both CD4 and CD8 T cells on glucose for Ca 2+ -NFAT1 signaling in glucose-poor conditions. Next, we examined whether PCK1-OE could enhance the antitumor responses of tumor-infiltrating Trp-1 CD4+ T cells. To this end, PCK1-OE or control Trp-1 CD4+ T cells were adoptively transferred into mice that contained engrafted B16 melanomas. Strikingly, PCK-OE increased Trp-1 CD4+ T cell production of IFNg and CD40L over that of control cells in the tumors, but not in the spleen or draining lymph nodes where glucose is more abundant (Figure 6E ). Additionally, relatively higher amounts of costimulatory ligand (CD86) and MHC class I and II expression were observed on TAMs in mice that received PCK1-OE Trp-1 CD4+ T cells compared to those that received control cells ( Figure 6F ), suggesting that restored effector functions by PCK1-OE Trp-1 CD4+ T cells promoted the maturation of TAMs. Most importantly, transfer of PCK1-OE Trp-1 CD4+ T cells suppressed melanoma growth ( Figure 6G ) and prolonged the survival of B16 melanoma-bearing mice ( Figure 6H ) compared to the control T cells. Of note, a similar suppression in tumor growth was observed in separate experiments when PCK1 was overexpressed in Pmel CD8+ T cells, specific for the melanoma antigen gp100 (Figures S6D and S6E ). Taken together, our results provide strong evidence that metabolic reprogramming of both CD4 and CD8 T cells is a promising strategy to boost effector functions of tumor-specific T cells in nutrient stressed conditions.
DISCUSSION
It is well appreciated that deregulated metabolism drives tumor cell growth, but it is underappreciated how this affects the metabolic or functional states of cells that infiltrate tumors (Pearce et al., 2013) . Do cancer cells play a ''metabolic tug-ofwar'' with immune cells in tumors? Our work suggests they may because tumors with elevated rates of glycolytic activity were better able to elude T cell immunosurveillance. Further, TILs displayed signs of glucose deprivation, including impaired production of IFNg and CD40L, but increased expression of TGFb and genes associated with T cell anergy. This led to the discovery that glycolysis controls T cell Ca 2+ -NFAT Data shown are representative of two (D) and three (C) independent experiments or cumulative of two (F) (n = 2-3 mice/group/experiment), three (B, E) (n = 2-3 mice/group/experiment), and four (G and H) independent experiments (n = 3-4 mice/group/experiment). Data are expressed as mean ± SD (B and F) or mean ± SEM (E) and *p < 0.05 by unpaired Student's t test.
signaling and effector functions via the glycolytic metabolite PEP. Importantly, manipulation of this pathway by metabolically reprogramming TILs to increase PEP production yielded stronger anti-tumor responses. This work reveals that a glucose-poor tumor microenvironment can impose immunosuppressive properties on TILs and provides critical proof-of-concept evidence that metabolic reprogramming of tumor-specific T cells can be an adjunct form of immunotherapy.
In addition to other well-known immunosuppressive factors, our work indicates that glucose deprivation is another critical environmental restriction in solid tumors that restrains the tumoricidal functions of infiltrating tumor-specific CD4+ T cells. Support for this model also stems from studies showing that tumor-specific T cells regain effector function after being cultured in vitro for a short period of time (6-24 hr) in nutrient replete conditions (Wang et al., 2011b) . Targeted inhibition of oncogenes, such as BrafV600E and KrasG12D, can stimulate T cell infiltration and production of IFNg in tumors, and it is possible that these effects stem from their suppression of tumor cell aerobic glycolysis (Ho et al., 2014; Ying et al., 2012) . However, further in vivo analyses are required to determine if tumor cells restrict glucose to infiltrating T cells through their own glycolytic activities and if this contributes to an immunosuppressive tumor microenvironment. Given that PD-1 signaling suppresses Akt-mTOR pathway and aerobic glycolysis (Parry et al., 2005; Staron et al., 2014) , the therapeutic effects of anti-PD-1 immunotherapy will most certainly rely on TILs reengaging aerobic glycolysis to regain proliferation and function. Indeed, rapamycin treatment abrogated the therapeutic effects of anti-PDL1 blockade on exhausted CD8 T cells during chronic viral infection (Staron et al., 2014) . That both tumor cells and activated T cells share similar requirements for anabolic metabolism raises important considerations for designing drug treatments that combine metabolically targeted therapies with immunotherapy. For example, drugs that suppress tumor cell glycolysis may have poor efficacy long-term because of their unintended effects on TIL function. Therefore, as new treatments are tested, the effects of anti-cancer drugs on the metabolism and function of tumor infiltrating immune cells should be considered and examined.
It is clear that certain metabolic pathways serve as ''metabolic checkpoints'' to control T cell activation and function, but mechanistically how this occurs is not well understood. Our study uncovers a mechanism through which the glycolytic intermediate PEP regulates the amplitude of Ca 2+ flux and NFAT activation to fine-tune T cell effector function. Although PEP could inhibit SERCA activity and increase its oxidative state, the precise molecular mechanism(s) by which this occurs remains unknown. Possibly PEP directly conjugates to or oxidizes cysteine residues on SERCA or alternatively PEP could serve as a high-energy phosphate donor to phosphorylate SERCA or other proteins that inhibit its activity (Vander Heiden et al., 2010) . Future biochemical studies are needed to precisely characterize which residues in SERCA, if any, are modified by PEP. Metabolic flexibility allows activated T cells to adapt to changes in glucose availability by utilizing alternative substrates for energy production (Blagih et al., 2015; Frauwirth et al., 2002) . Possibly, TILs become dependent on other carbon sources, such as lactic acid and free fatty acids (FFAs) abundant in the tumor microenvironment, and this not only changes the metabolic activities of TILs, but also their effector functions. Indeed, it is interesting to consider which carbon sources are used by the PCK-1 overexpressing T cells to manufacture PEP when glucose-deprived; our preliminary studies in vitro suggest that both lactic acid and FFAs may be involved (data not shown). Future in-depth metabolite profiling of TILs will help to characterize the nutrients they consume and the metabolic pathways they exercise in vivo, through which, one may develop more robust methods to harness anti-tumor T cell responses via metabolic manipulation.
Overall, our findings describe a metabolic checkpoint for T cell activity in tumors in which a glycolytic metabolite, PEP, serves as an intracellular sensor for glucose availability in the environment to regulate T cell activation and production of effector molecules. Together with another recent discovery identifying a secondary role for GAPDH in inhibiting IFNg mRNA translation in T cells ), these finding demonstrate that both metabolites and metabolic enzymes have adopted additional roles as metabolic checkpoint regulators to control specialized functions in T cells. From a therapeutic standpoint, better delineation of the metabolic pathways or enzymes differentially utilized by cancer cells and cancer-specific T cells could reveal vulnerable drugtargets in cancer cells. Additionally, rewiring the metabolic activity of TILs, as demonstrated herein and elsewhere (Doedens et al., 2013) , could pose a new strategy for enhancing the potency and durability of ACT.
EXPERIMENTAL PROCEDURES
Mice, Tumor Engraftment, and Tumor Induction The inducible mouse model of melanoma was previously described (Dankort et al., 2009 ) and Trp-1 TCR transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME). For melanoma cell engraftment, 2x105 B16 or Braf/Pten melanoma cells were suspended in 50 ml of PBS and then injected subcutaneously into wild-type C57BL/6 mice (Jackson Laboratory). All mouse experiments were performed according to the approved procedures of the Yale Institutional Animal Care and Use Committee.
ER Vesicle Isolation and Calcium Uptake Assay
Jurkat cells were cultured in glucose-free RPMI with 10% dialyzed FBS in the indicated conditions for 30 min. ER microsomal fractions were then isolated as previously described (Ho et al., 2011) . ER vesicles were then analyzed by a calcium uptake assay with 45CaCl2 as the tracer of calcium uptake, as previously described (Borge and Wolf, 2003) . For analysis of the effect of PEP on ER calcium uptake, the calcium uptake assay was performed in the presence of 6 mM PEP.
Fluorescence Labeling of SERCA Thiol Groups ER microsomal fractions were then isolated from Jurkat cells cultured in glucose-free RPMI with 10% dialyzed FBS in 10 mM glucose or 0.1 mM glucose for 30 min. Two hundred micrograms of ER microsomal fraction was re-suspended in 20 mM sodium phosphate (pH7.4) buffer and then incubated with control vehicle, 1 mg/ml PEP, 1 mg/ml fosphomycin, 5 mM H2O2 or 1 mM b-mercaptoethanol for 10 min at 37 C. 200 mM Thiol-fluorescent probe IV (EMD Millipore, Billerica, MA) in the presence of 1% SDS for 30 min at 37 C.
Then the reaction mixture was subjected for immunoprecipitation of SERCA or control IgG. The fluorescence intensity of the immunoprecipiates was then determined.
Statistical Analysis
Results were presented as mean ± SD or mean ± SEM and statistical significance was examined by an unpaired Student's t test. p value < 0.05 was considered as statistically significant.
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